Innovation Event


Category: Life Sciences

Place: Halle 7, Gundeldingerfeld, Dornacherstrasse 192, 4053 Basel

Stephan Emmerth


Stephan Emmerth

PhD | Senior Project Manager Biotech, Business Development Senior Manager BaseLaunch

Tel. +41 61 295 50 17

event Life Sciences


Molecular Partners: Road to IPO and beyond

Starting and financing a biotech company is not a piece of cake. But closing partnerships and progressively bigger financing rounds, bringing molecules into clinical development and eventually floating a company on the stock market is even harder. Molecular partners has done all of that. The biotech, which emanated out of research of the University of Zürich, is developing DARPins® therapeutics, a new class of small protein therapeutic agents, with high-specificity, potency and versatility in one therapy. The lead compound is partnered with Allergan and currently in phase III. And in 2014, the company successfully floated on the Swiss Stock Exchange.
We are delighted to having Dr. Patrick Amstutz, CEO and co-founder of Molecular Partners, talking about this exciting story and sharing lessons learned along the way.
The event takes place at Halle 7 (Gundeldingerfeld, Dornacherstrasse 192) in Basel on 3 October 2017, starting at 19:00. Doors are open at 18:45.


18:45 Door opening
19:00 Introduction
19:05 Dr. Patrick Amstutz «Molecular Partners: Road to IPO and beyond” and Q&A
19:50 Networking apero

The event is free of charge but registration is compulsory.


CV Patrick Amstutz

Dr. Patrick Amstutz is Chief Executive Officer at Molecular Partners since November 2016. From 2014 to 2016 he was Chief Operating Officer and from 2006 to 2014 Chief Business Officer. He co-founded Molecular Partners and has been a member of the company’s management team since its inception in 2004. As Chief Operating Officer and Chief Business Officer, Dr. Amstutz was responsible for business development, alliance management and research and development (R&D) operations. He has established a wide range of commercial collaborations and licensed several key technologies. Dr. Amstutz holds a Master of Science from the ETH Zurich and a PhD in Molecular Biology from the University of Zurich.